Sign in to view content

Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics

David R Lally, MD

Video
Published 2021

Related

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
ARMD With Geographic Atrophy, Peripheral Degeneration
James B. Soque, CRA, OCT-C, COA, FOPS
Pamela Ann Weber, MD
Retina Image Bank: Images of the Week
2013

Category: AMD-Non-Neovascular

See more